Devita, Hellman, and Rosenberg's Cancer

LWBK1006-15 LWW-Govindan-Review December 7, 2011 19:5

166 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 15.23. Regarding therapeutic response assessment, which is TRUE?

A. There are three categories of response: complete response, partial

response, and disease progression.

B. Response Evaluation Criteria in Solid Tumors (RECIST) rely on bidi-

rectional measurements.

C. Partial response represents less than 25% reduction in the sum of the

tumor cross-products.

D. One shortcoming of the RECIST is the lack of inclusion of bone

marrow involvement by neoplasm.

E. There is no role in using perfusion techniques to assess tumor

response.

Question 15.24. Regarding brain neoplasms, which is TRUE?

A. Cross-sectional imaging is a highly specific way to distinguish recur-

rent tumor from radiation change.

B. MRI with contrast is superior to CT for the evaluation of sellar

lesions.

C. CT plays no role in the presurgical evaluation when high-quality MRI

is used.

D. Because of high spatial resolution, MRI does not require contrast to

detect cerebral lesions.

E. Functional MRI is a great way to look at the behavior of small nodules

and avoid overstaging a patient.

Question 15.25. Regarding head and neck cancers, which is TRUE?

A. MRI is favored over CT when the lesion is in the upper aerodigestive

tract near the skull base.

B. Neck CT with intravenous contrast is better than endoscopy in the

evaluation of small mucosal lesions of the aerodigestive tract.

C. There is no role for PET/CT in head and neck cancers because intra-

venous contrast material is not used.

D. CT does not delineate bone involvement in paranasal sinus tumors.

Question 15.26. Regarding lung cancer, which is TRUE?

A. Chest radiography screening results in improved mortality.

B. CT screening further improves mortality because smaller lesions are

detected.

C. MDCT can accurately predict chest wall or mediastinal invasion in

greater than 95% of patients.

D. MRI is useful in the evaluation of superior sulcus tumors.

E. PET/CT obviates the need for any additional imaging in the staging

of clinically suspected metastatic non-small cell lung cancer.